Celcuity named David W. Gryska to its board of directors as the company moves into commercial-stage operations following its first FDA approval for Revtorpyk.
Gryska brings more than 35 years of life sciences finance and strategy experience. His background includes serving as executive vice president and chief financial officer at Incyte and as senior vice president and chief financial officer at Celgene. He also held CFO roles at Scios and spent part of his career as a partner at Ernst & Young.
Over the past 25 years, Gryska has served on the boards of eight public biotechnology companies. He currently sits on the board of Definium Therapeutics and previously served more than 15 years on Seagen’s board, along with board roles at Forte Biosciences, Aerie Pharmaceuticals and GW Pharmaceuticals.
The appointment comes as Celcuity prepares for the launch of Revtorpyk, its first FDA-approved product, in advanced breast cancer. The company is also advancing multiple clinical programs, including its phase 3 Viktoria-2 trial in advanced breast cancer and its phase 1b/2 Celc-G-201 study in metastatic castration-resistant prostate cancer. As a result of these announcements, the company's shares have moved -5.52% on the market, and are now trading at a price of $75.13. For more information, read the company's full 8-K submission here.
